Percutaneous aortic valve replacement

Medtronic Evolut TAVR System Receives Updated U.S. Labeling Revising Precaution for Treatment of Low-Risk Patients with Bicuspid Aortic Stenosis

Retrieved on: 
Friday, August 21, 2020
Circulatory system, Cardiovascular system, Medical specialties, Congenital heart defects, RTT, Cardiac surgery, Bicuspid aortic valve, Aortic valve, Aortic stenosis, Aortic valve replacement, Percutaneous aortic valve replacement

The revised commercial labeling includes recommendations heart teams should consider when assessing TAVR as a potential treatment option for bicuspid patients, including patients anatomical characteristics, age, long term durability, and the existing clinical data.

Key Points: 
  • The revised commercial labeling includes recommendations heart teams should consider when assessing TAVR as a potential treatment option for bicuspid patients, including patients anatomical characteristics, age, long term durability, and the existing clinical data.
  • Bicuspid aortic valve disease is a congenital heart defect that is prevalent in 1-2% of the population and accounts for nearly half of all severe symptomatic aortic stenosis patients in the U.S.
  • The Evolut TAVR platform including the Evolut R, Evolut PRO and Evolut PRO+ TAVR Systems is indicated for symptomatic severe AS patients across all risk categories (extreme, high, intermediate and low) in the U.S.
  • In addition, bicuspid aortic valve patients across all risk categories may be candidates for TAVR in the U.S.

Anteris Technologies to Host TAVR Key Opinion Leader Symposium Moderated by Matt Miksic of Credit Suisse on July 20th, 2020

Retrieved on: 
Thursday, July 9, 2020
Cardiac surgery, Medical specialties, Medicine, Clinical medicine, Aortic valve replacement, Valve replacement, Aortic valve, Heart valve, AVR, Percutaneous aortic valve replacement, Aortic valve repair

BRISBANE, Australia and EAGAN, Minn., July 09, 2020 (GLOBE NEWSWIRE) -- Anteris Technologies Limited (ASX:AVR), a structural heart company advancing the DurAVRvalve, a novel aortic valve replacement solution, announced today that it will host a key opinion leader symposium on Monday, July 20, 2020 at 11:00AM EDT.

Key Points: 
  • BRISBANE, Australia and EAGAN, Minn., July 09, 2020 (GLOBE NEWSWIRE) -- Anteris Technologies Limited (ASX:AVR), a structural heart company advancing the DurAVRvalve, a novel aortic valve replacement solution, announced today that it will host a key opinion leader symposium on Monday, July 20, 2020 at 11:00AM EDT.
  • A key area of emphasis will be addressing how current TAVR solutions are suitable for this newly approved patient demographic, what challenges they have, and what are the leading next generation technologies that are in development.
  • Anteris Technologies Ltd. is a structural heart company focused on delivering clinically superior solutions that create life-changing outcomes for patients.
  • With these advantages, Anteriss best-in-class ADAPT tissue combined with its valve design has the potential to solve the problems associated with current aortic valve replacement options which are durability and preventing valve degradation.

Protaryx Medical Announces $8.3M in Funding for First-in-Class Technology for Left Atrial Access in Transcatheter Cardiac Procedures

Retrieved on: 
Tuesday, June 30, 2020
Science, Cardiology, Research, Surgery, Health, Hospitals, Technology, Other Technology, Medicine, Medical specialties, Clinical medicine, Catheter, Port, Interventional cardiology, Percutaneous aortic valve replacement, Protaryx Medical, Ajax Health, UM Ventures

Protaryx Medical, a company committed to reimagining access to the left atrium for transcatheter cardiac procedures, today announced that it has raised $8.3 million in funding to develop the companys first-in-class device for precision transseptal access to the left atrium during structural heart and catheter ablation procedures.

Key Points: 
  • Protaryx Medical, a company committed to reimagining access to the left atrium for transcatheter cardiac procedures, today announced that it has raised $8.3 million in funding to develop the companys first-in-class device for precision transseptal access to the left atrium during structural heart and catheter ablation procedures.
  • Were pleased to partner with the experienced team at Ajax Health to leverage its proven expertise and reputation for supporting successful emerging medical device companies.
  • The innovative Protaryx device is designed with the goal of simplifying transseptal access for physicians, which may lead to fewer complications and improved outcomes for patients.
  • Protaryx Medical is a medical device company committed to reimagining access to the left atrium for transcatheter cardiac procedures.

Medtronic Evolut TAVI System Receives Expanded Indication in Europe to Treat Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

Retrieved on: 
Monday, June 22, 2020
Circulatory system, Medical specialties, Cardiovascular system, Cardiac surgery, Valvular heart disease, RTT, Congenital heart defects, Percutaneous aortic valve replacement, Aortic stenosis, Bicuspid aortic valve, Cardiology, Aortic valve

The Evolut TAVI platform also received a new indication approval that allows for the treatment of patients with bicuspid aortic valves who are at intermediate, high and extreme risk of surgical mortality.

Key Points: 
  • The Evolut TAVI platform also received a new indication approval that allows for the treatment of patients with bicuspid aortic valves who are at intermediate, high and extreme risk of surgical mortality.
  • The Evolut TAVI System, with its excellent hemodynamics, allows for improved heart function that helps many patients resume their pre-aortic stenosis activity.
  • With this approval, the Evolut TAVI platform is now indicated in Europe for severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low), and includes new labeling that allows for the treatment of patients with bicuspid aortic valves for patients at extreme, high and intermediate risk of surgical mortality.
  • The Evolut TAVR platform is indicated in the U.S. for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low).

Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China

Retrieved on: 
Monday, June 8, 2020
Medicine, Medical specialties, Cardiac surgery, Heart, Cardiology, Edwards Lifesciences, Percutaneous aortic valve replacement, Prosthetics, Aortic valve replacement, Aortic valve, Heart valve

The SAPIEN 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN transcatheter heart valves.

Key Points: 
  • The SAPIEN 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN transcatheter heart valves.
  • The approval for high-risk and extreme-risk patients in China was supported by the China SAPIEN 3 study, which complements a highly robust set of clinical outcomes from three randomized controlled PARTNER studies, along with excellent real-world results.
  • "This approval marks a major milestone for Chinese physicians and their patients living with severe AS in need of alternatives to open-heart surgery," said Larry L. Wood, Edwards' corporate vice president, transcatheter aortic valve replacement.
  • Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, and SAPIEN 3, are trademarks of Edwards Lifesciences Corporation.

Transcatheter Aortic Valve Replacement (TAVR) Market 2020-2024: Transfemoral, Transapical and Transaortic

Retrieved on: 
Thursday, April 23, 2020
Medicine, Medical specialties, Cardiac surgery, Clinical medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Valve replacement, Aortic valve, John G. Webb

DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global transcatheter aortic valve replacement (TAVR) market by procedure can be segmented into the following three categories: transfemoral, transapical and transaortic.
  • The global transcatheter aortic valve replacement (TAVR) market by region can be segmented as follows: the US and outside the US.
  • The report provides a comprehensive analysis of the global transcatheter aortic valve replacement (TAVR) market, segmented into transfemoral, transapical and transaortic procedures.

Transcatheter Aortic Valve Replacement (TAVR) Markets, 2020-2024 | Includes Company Profiles of Edwards Lifesciences Corp, Medtronic, Boston Scientific Corp and Abbott Laboratories

Retrieved on: 
Thursday, April 23, 2020
Medicine, Medical specialties, Cardiac surgery, Clinical medicine, Percutaneous aortic valve replacement, Valve replacement, Aortic valve, Edwards Lifesciences, Medtronic, Boston Scientific, Army Reserve

DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Transcatheter Aortic Valve Replacement (TAVR) Market: Size, Trends and Forecasts (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Transcatheter Aortic Valve Replacement (TAVR) Market: Size, Trends and Forecasts (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global TAVR market has increased at a significant CAGR during the years 2015-2019 and projections are made that the market would rise in the next four years i.e.
  • Further, the major players dominating the global TAVR market are Edwards Lifesciences Corporation, Medtronic plc, Boston Scientific Corporation, and Abbott Laboratories.
  • This report provides an in-depth analysis of the global TAVR market by value, by volume, by procedure, by region, etc.

Abbott's TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair

Retrieved on: 
Thursday, April 9, 2020
Medicine, Cardiac surgery, Medical specialties, Circulatory system, Valvular heart disease, Heart valves, Interventional cardiology, MitraClip, Heart valve, Valve replacement, Mitral valve, Percutaneous aortic valve replacement

With the CE Mark designation, Abbott's TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world.

Key Points: 
  • With the CE Mark designation, Abbott's TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world.
  • TriClip leverages the same clip-based technology as MitraClip but has a differentiated delivery system designed specifically for delivery to the tricuspid valve.
  • Abbott also recently announced CE Mark approval of its Tendyne Transcatheter Mitral Valve Implantation System, a minimally invasive valve replacement option to add to its portfolio of mitral solutions.
  • The TriClip Transcatheter Tricuspid Valve Repair System is an investigational device only in the U.S.

Global Transcatheter Aortic Valve Replacement Market: Insights, Trends & Forecast (2020-2024) - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 9, 2020
Surgery, Health, Medical devices, Medicine, Medical specialties, Cardiac surgery, Circulatory system, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic stenosis, Aortic valve, Valve replacement, Heart valve, John G. Webb

The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The market growth of transcatheter aortic valve replacement (TAVR) was supported by various factors like rising prevalence of aortic stenosis, increasing GDP per capita, growing obese population and increasing healthcare spending.
  • The global transcatheter aortic valve replacement (TAVR) market by procedure can be segmented into the following three categories: transfemoral, transapical and transaortic.
  • The global transcatheter aortic valve replacement (TAVR) market by region can be segmented as follows: the US and outside the US.

Global Transcatheter Aortic Valve Replacement (TAVR) Market: Size, Trends and Forecasts (2020-2024) - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 2, 2020
Health, Medical devices, Cardiology, Medicine, Medical specialties, Cardiac surgery, Clinical medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Valve replacement, Aortic valve, Marketplace, Army Reserve

2.4 Transcatheter Aortic Valve Replacement (TAVR) Segmentation: An Overview

Key Points: 
  • 2.4 Transcatheter Aortic Valve Replacement (TAVR) Segmentation: An Overview
    3.1.3 Global TAVR Market by Procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation)
    3.1.4 Global TAVR Market by Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
    3.1.5 Global TAVR Market Volume by Region (The US, China, and ROW)
    4.1 North America TAVR Market: An Analysis
    4.3 Asia Pacific TAVR Market: An Analysis
    4.4 Middle East & Africa TAVR Market: An Analysis
    4.5 Latin America TAVR Market: An Analysis